Pieris Pharmaceuticals Inc (NASDAQ:PIRS) shares saw strong trading volume on Monday . 5,265,625 shares were traded during mid-day trading, an increase of 1,166% from the previous session’s volume of 415,788 shares.The stock last traded at $5.33 and had previously closed at $4.75.

Several analysts have issued reports on the company. Zacks Investment Research downgraded Eisai from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 24th. ValuEngine raised XOMA from a “sell” rating to a “hold” rating in a research note on Friday, May 24th. Robert W. Baird assumed coverage on TJX Companies in a research note on Monday, May 13th. They issued an “outperform” rating and a $63.00 price target on the stock. HC Wainwright set a $267.00 price target on Sarepta Therapeutics and gave the company a “buy” rating in a research note on Monday, June 17th. Finally, Cowen reissued a “buy” rating on shares of Alector in a research note on Monday, May 13th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $5.67.

The company has a market cap of $263.94 million, a P/E ratio of -10.66 and a beta of 1.25. The firm’s fifty day moving average price is $4.51.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings data on Friday, May 10th. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.02). The company had revenue of $8.55 million during the quarter, compared to the consensus estimate of $7.85 million. Pieris Pharmaceuticals had a negative net margin of 84.75% and a negative return on equity of 64.64%. Research analysts anticipate that Pieris Pharmaceuticals Inc will post -0.85 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently made changes to their positions in PIRS. Bank of America Corp DE grew its holdings in shares of Pieris Pharmaceuticals by 793.1% in the 4th quarter. Bank of America Corp DE now owns 277,370 shares of the biotechnology company’s stock valued at $739,000 after acquiring an additional 246,312 shares in the last quarter. American Century Companies Inc. grew its holdings in shares of Pieris Pharmaceuticals by 37.5% in the 4th quarter. American Century Companies Inc. now owns 650,725 shares of the biotechnology company’s stock valued at $1,731,000 after acquiring an additional 177,569 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in shares of Pieris Pharmaceuticals in the 4th quarter valued at about $374,000. Granite Investment Partners LLC bought a new position in shares of Pieris Pharmaceuticals in the 1st quarter valued at about $443,000. Finally, Wedge Capital Management L L P NC grew its holdings in shares of Pieris Pharmaceuticals by 23.6% in the 1st quarter. Wedge Capital Management L L P NC now owns 525,324 shares of the biotechnology company’s stock valued at $1,760,000 after acquiring an additional 100,308 shares in the last quarter. Institutional investors own 59.68% of the company’s stock.

Pieris Pharmaceuticals Company Profile (NASDAQ:PIRS)

Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.

Featured Story: What is the formula for the cash asset ratio?

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.